A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E.

Autor: Assouline S; Segal Cancer Centre, Lady Davis Institute, Jewish General Hospital, McGill University katherine.borden@umontreal.ca sarit.assouline@mcgill.ca., Culjkovic-Kraljacic B; Institute for Research in Immunology and Cancer & Dept. of Pathology and Cell Biology, Université de Montréal., Bergeron J; Hôpital Maisonneuve-Rosemont, Montréal, QC, Canada., Caplan S; Segal Cancer Centre, Lady Davis Institute, Jewish General Hospital, McGill University., Cocolakis E; Segal Cancer Centre, Lady Davis Institute, Jewish General Hospital, McGill University., Lambert C; Segal Cancer Centre, Lady Davis Institute, Jewish General Hospital, McGill University., Lau CJ; Segal Cancer Centre, Lady Davis Institute, Jewish General Hospital, McGill University., Zahreddine HA; Institute for Research in Immunology and Cancer & Dept. of Pathology and Cell Biology, Université de Montréal., Miller WH Jr; Segal Cancer Centre, Lady Davis Institute, Jewish General Hospital, McGill University., Borden KL; Institute for Research in Immunology and Cancer & Dept. of Pathology and Cell Biology, Université de Montréal katherine.borden@umontreal.ca sarit.assouline@mcgill.ca.
Jazyk: angličtina
Zdroj: Haematologica [Haematologica] 2015 Jan; Vol. 100 (1), pp. e7-9. Date of Electronic Publication: 2014 Nov 25.
DOI: 10.3324/haematol.2014.111245
Databáze: MEDLINE